Two FDA advisory committees will meet Nov. 18 to consider whether efficacy and safety data from a small, one-arm, Phase III trial are adequate to support approval of Telesta Therapeutics Inc.'s novel and complex biologic treatment for bladder cancer.
FDA's Cellular, Tissue and Gene Therapies and the Oncologic Drugs advisory committees will discuss the safety and efficacy of Mycobacterium...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?